Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.7% - Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price was down 4.7% on Friday . The company traded as low as $9.63 and last traded at $9.74. Approximately 48,133 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 80,171 shares. The stock had previously closed at $10.22.

Analyst Upgrades and Downgrades

Separately, Noble Financial assumed coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating on the stock.

Gyre Therapeutics Stock Up 3.0 %

The firm has a fifty day moving average of $11.27 and a 200-day moving average of $12.16. The firm has a market cap of $888.38 million, a P/E ratio of 189.80 and a beta of 1.93.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Insider Activity

In other news, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 36,054 shares of company stock valued at $407,317 in the last 90 days. 19.52% of the stock is owned by company insiders.

Remove Ads

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GYRE. Wells Fargo & Company MN grew its holdings in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock worth $1,386,000 after acquiring an additional 918 shares in the last quarter. Barclays PLC grew its stake in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after acquiring an additional 1,255 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Gyre Therapeutics by 11.1% in the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after acquiring an additional 1,389 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after purchasing an additional 1,996 shares during the period. Institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.